



Kallikrein 14 Signalling through Proteinase-Activated Receptors

Katerina Oikonomopoulou^{1,2}, Kristina K. Hansen^{3,4}, Mahmoud Saifeddine^{3,4}, Illa Tea^{3,4}, Patricia Andrade-Gordon⁵, Graeme S. Cottrell⁶, Nigel W. Bennett⁶, Nathalie Vergnolle³, Eleftherios P. Diamandis^{1,2} and Morley D. Hollenberg^{3,4}

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto; ²Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto;
³Department of Pharmacology & Therapeutics, and ⁴Department of Medicine, University of Calgary, Calgary; ⁵Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania, ⁶Departments of Surgery and Physiology, University of California, San Francisco

OVERVIEW

- Proteinase-activated receptors (PARs): a family of G-protein coupled receptors activated by serine proteinases via a proteolytically revealed ‘tethered ligand’ (Fig. 1). Four family members (Fig. 2); PARs 1, 2 and 4 signal to cells.
- Human kallikreins (hKs): A 15-member family of secreted serine proteinases implicated in tumour progression and cell survival (Fig. 4).
- hK14: a trypic kallikrein; wide tissue distribution, implicated in breast and ovarian cancer (Fig. 5 and 6).
- The mechanism of kallikrein action is not yet known: Although some targets have been identified (e.g. extracellular matrix; pro-UPA), the mechanism whereby kallikreins regulate tissue function is not known.
- We hypothesized that hK14, as a prototype kallikrein, modulates cell survival and tumour growth by regulating (activating or inactivating/dis-arm) proteinase-activated receptor (PAR) signalling.
- Main conclusions: hK14 activated PAR₁ in cultured cells (Ca⁺⁺ signalling) and caused PAR₁-mediated relaxation of rat and murine vascular tissue. In addition, hK14 had a dual action on PAR₁, depending on the enzyme concentration (principally dis-arm). In human platelets, hK14 was able to cause aggregation by activating PAR₄ whilst dis-arm PAR₁.
- Significance of study: In the setting of human tumours, known to be platelet-rich, hK14 would trigger platelet aggregation and the preferential release of platelet endostatin rather than VEGF via PAR₁ (PNAS 2005;102(1):216-20). Also, by targeting PAR₂ and/or PAR₄, hK14 could participate in tumour growth and survival, as well as in the inflammatory responses during cancer progression.

Figure 4: Human Kallikreins




Figure 5:
Kallikreins are secreted enzymes e.g. hK14

Figure 6: Kallikrein expression
Tissue Expression of Kallikreins (RT-PCR) Kallikreins and cancer

- PSA/hK3 is utilized to monitor prostate cancer patients
- hK6 (Zyme / proteinase M / Neurosin), hK10 (NESI), hK11, hK8, hK5 and hK14 may represent novel ovarian cancer biomarkers
- hK11 may represent a novel prostate cancer biomarker
- hK5 and hK14 may represent novel breast cancer biomarkers
- hKs can cleave several pro-uPA, GFs and ECM proteins

Figure 1: Mechanism of PAR activation (activation by proteolysis)




Figure 2: The PAR family

4 PARs are known in rodents and humans

Receptor	Major Activating proteinases	Some Disarming proteinases
PAR ₁	Thrombin	Trypsin, Cathepsin G
PAR ₂	Trypsin, Tryptase	Elastase
PAR ₃	Thrombin	Cathepsin G
PAR ₄	Thrombin	Unknown, Kallikreins ?

Steinhoff M, et al, Endocr Rev, 2005;26:1-43

Materials and Methods

Calcium signalling

- Calcium signalling assay in human HEK cells (PAR₁ and 2 / PAR₄) and rat KNRK (PAR₁)
- Method: Incubate cells with Ca⁺⁺ indicator (Fluo-3) → examine for cross-desensitization of PARs,

using PAR-activating peptides, agonists and antagonists:

- TFLLR-NH₂ - selective desensitization of PAR₁, 2
- SFLLR-NH₂ - selective desensitization of PAR₁, 2
- AYPPGKF-NH₂ - selective desensitization of PAR₄
- Trypsin and/or Thrombin
- Phenylephrine and Acetylcholine
- L-NAME - inhibitor of NOS-mediated aorta relaxation

- Bioassays
- Aorta endothelium: Contraction / relaxation (PAR₂)
- Human (PAR₁ and PAR₃) and Rat (PAR₁) platelets: Aggregation / Ca⁺⁺ assays
- Inflammation

Kawabata A, et al, JPET 1999;288: 358-70
Hollenberg MD, et al, Can J Physiol Pharmacol, 1997;75:832-41
Hollenberg MD, et al, Can J Physiol Pharmacol, 2001;79:439-42
Vergnolle N, et al, Br J Pharmacol, 1999;127:1083-90

Results


1. hK14 can cleave within synthetic PAR 1, 2 and 4 peptides (designed based on the cleavage/activation motifs; Fig.3)

Tethered ligand sequence		
Receptor	Trypsin (3.5 U/ml)	hK14 (4.3 U/ml)
hPAR ₁	NATLDPK / SFLLRNPNDKYE	NATLDPK / SF / LLR / NPNDKYE
hPAR ₂	GTNRSSKGR / SLIGK / V / DGTSH VTGK / GVT	GTNRSSKGR / SLIGK / VDGTSHVTGK / GVT
hPAR ₄	GDDSTPSILPAPR / GYPGQV	G / DDSTPSILPAPR / GY / PGQV
rPAR ₂	GPNSKGR / SLIGRLDTPY / G / GC	GPNSKGR / SLIGRLDTPY / GG / C
rPAR ₄	L / NESK / SPDKPNPR / GFPGK	LNESKSPDKPNPR / GFPGK / P


Only the **intact ligand sequences**, that would remain tethered to the receptor, would result in signalling. Other potential cleavage sites would dis-arm the receptor, preventing receptor activation.

Oikonomopoulou K, et al, Biol Chem 2006


2. Kallikrein 14 can selectively disarm PAR₁ (lower concentrations), whilst activating PARs 2 and 4; Ca⁺⁺ in HEK cells



3. Kallikrein 14 can cause platelet aggregation and Ca⁺⁺ signalling through PAR₄ in isolated platelets



4. Kallikreins can cause aorta relaxation, mediated through PAR₂ activation



Conclusions; Kallikreins can regulate PAR activity

